Palforzia Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of peanut allergies, improved diagnosis of food hypersensitivities, clinical validation of oral immunotherapy approaches, rising awareness among pediatric populations, expansion of specialty allergy clinics.

The growth in the forecast period can be attributed to growing adoption of disease-modifying allergy treatments, expansion of food allergy management programs, rising investments in immunotherapy innovation, broader regulatory approvals for OIT products, increasing demand for long-term allergy risk reduction. Major trends in the forecast period include increasing adoption of oral immunotherapy for food allergies, increasing focus on pediatric allergy treatments, expansion of structured desensitization protocols, rising demand for preventive anaphylaxis therapies, enhanced monitoring of treatment safety.

The increasing prevalence of allergies is expected to drive the growth of the Palforzia market going forward. Allergies occur when the immune system reacts abnormally to substances (allergens) that are normally harmless, such as pollen, dust, or certain foods, causing symptoms like sneezing, rashes, or severe reactions such as anaphylaxis. The rise in allergies is attributed to environmental changes, pollution, genetic predisposition, and lifestyle factors, including diet, hygiene, and increased exposure to allergens. Palforzia provides oral immunotherapy for peanut allergies by gradually desensitizing the immune system to peanut proteins, reducing the severity of allergic reactions, including anaphylaxis, caused by accidental peanut exposure. For instance, in August 2024, according to NHS England, a UK-based publicly funded healthcare system, hospital admissions for individuals with allergies and anaphylaxis increased to 32,300 in 2023-24, up from 25,702 in 2022-23. Therefore, the increasing prevalence of peanut allergies is driving the Palforzia market.

Major companies in the Palforzia market are focusing on developing innovative solutions, such as FDA-approved oral immunotherapy (OIT) treatments, to meet rising demand for safer, more effective, and clinically validated peanut allergy therapies. Oral immunotherapy delivers controlled, gradually increasing doses of an allergen to desensitize the immune system, providing a long-term treatment option compared with traditional avoidance strategies, which do not modify immune response. For instance, in July 2024, Stallergenes Greer, a Switzerland-based company, received FDA approval to extend the pediatric indication for Palforzia (peanut (Arachis hypogaea) protein) oral immunotherapy. This treatment features a gradual dose escalation process in powder form, with dosage levels tailored to patient tolerance, supporting long-term allergy management globally.

In September 2023, Stallergenes Greer acquired Palforzia from Nestlé SA for an undisclosed amount. This acquisition allows Stallergenes Greer to strengthen its allergy treatment portfolio and expand into food allergy therapies. Nestlé SA, a Switzerland-based company, originally developed Palforzia as part of its nutrition, health science, and allergy treatment initiatives.

Major companies operating in the palforzia market are Stallergenes Greer International AG.

North America was the largest region in the palforzia market in 2025. The regions covered in the palforzia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the palforzia market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the palforzia market by increasing costs associated with imported pharmaceutical-grade peanut protein, encapsulation materials, quality testing equipment, and controlled manufacturing processes. North America and Europe are most affected due to strict regulatory requirements and reliance on specialized ingredient sourcing, while other regions face higher import-related costs. These tariffs are increasing therapy pricing and limiting rapid market expansion. However, they are also encouraging domestic ingredient processing, localized manufacturing capabilities, and long-term supply chain resilience.

The palforzia market research report is one of a series of new reports that provides palforzia market statistics, including palforzia industry global market size, regional shares, competitors with a palforzia market share, detailed palforzia market segments, market trends and opportunities, and any further data you may need to thrive in the palforzia industry. This palforzia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Palforzia is an oral immunotherapy (OIT) medication designed to reduce the severity of allergic reactions, including anaphylaxis, in individuals with a confirmed peanut allergy. It is approved for use in children and adolescents aged 4 to 17, with the option to continue treatment in older patients under medical supervision.

The main clinical indications for Palforzia include treatment of peanut allergy, the maintenance phase of oral immunotherapy (OIT), and peanut allergy with a risk of severe reactions. Peanut allergy management generally involves avoidance of peanuts and use of emergency medications to address severe reactions. It is distributed through retail pharmacies, specialty pharmacies, and healthcare facilities, and is used by end users such as hospitals, clinics, ambulatory care, and home care settings.

The palforzia market consists of sales of products such as pre-measured oral capsules and powder sachets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.